LoadSpring Collaborates with Google Cloud and SADA to Deliver Enhanced AI Solutions
10.12.2020 19:27:00 EET | Business Wire | Press release
LoadSpring Solutions, a leading provider of global managed cloud solutions, announces a strategic collaboration with Google Cloud and SADA to provide clients with enhanced project analytics via Artificial Intelligence and Business Intelligence solutions. LoadSpring will combine its application, support, and project expertise with SADA's delivery expertise and Google Cloud infrastructure, solutions, and capabilities in AI and ML to help clients eliminate risks while increasing their insights and data access to make critical business and project decisions in real-time.
As a global leader in hosting, integrating, and providing access to software application data for project and asset-intensive organizations, LoadSpring recognizes the importance of access to a global technology footprint. Its customers operate worldwide and expect the same performance and support, whether in the Americas, Europe, the Middle East, or Pan-Asia. The new alliance will accelerate customer benefits, including one-stop managed cloud services, centralized support, and improved project command and control through LoadSpring Cloud Platform.
"The strategic alignment between our organizations is significant. The investments Google Cloud, SADA, and LoadSpring, are making to deliver best-in-class cloud solutions is transformational for our clients. I'm truly excited about the prospect of hosting, accessing, and leveraging years of data during the project life-cycle," said Dean Edmundson, Chief Strategy Officer at LoadSpring.
"Organizations today have an opportunity to transform business processes and derive more value out of their data with cloud capabilities in AI, ML, and analytics," said Dave Hutchison, Managing Director, Worldwide Channels at Google Cloud. "We are excited that LoadSpring and SADA will collaborate to help businesses leverage Google Cloud infrastructure and technologies to do so, and look forward to working together to drive digital transformation."
"We're excited to partner with LoadSpring to help them maximize the value of their Google Cloud investment," stated Simon Margolis, VP of CE, SADA. "The combined strength of our offerings will help clients expand their cloud, Business Intelligence, AI, and ML capabilities to achieve better project results."
ABOUT LOADSPRING
Founded in 1999, LoadSpring is a global cloud solutions provider obsessed with offering the highest level of managed cloud services. LoadSpring delivers expert Project Management solutions and fast access to project data, Business Intelligence, and hundreds of best-of-breed project-based applications. Data safety is assured through their SOC 2 Type II security certification, providing an impenetrable cloud environment. Through their proprietary LoadSpring Cloud Platform and their soon-to-be-launched LoadSpring Marketplace, customers and partners get effortless app provisioning, higher productivity, and ROI – all while reducing the burden on their IT departments.
ABOUT SADA
SADA is a leading global provider of business and technology services empowering people to transform their work, their organizations, and the world. SADA teams have helped enterprise clients in healthcare, media, entertainment, retail, manufacturing, and the public sector achieve their boldest ambitions and solve their most complex problems. A Google Cloud Partner with multiple Specializations, SADA delivers continuous innovation, strong partnerships, and service excellence. This has led to numerous accolades and awards, including the Google Cloud Global Reseller Partner of the Year for 2018 and 2019, the Inc. 5000 Honoree list of America's Fastest Growing Private Companies for 14 straight years, and the 2020 Inc. list of America's Top 50 Workplaces. More info at www.sada.com.
For more information, contact Stacey Witt at switt@loadspring.com or visit www.loadspring.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201210005791/en/
Contact information
Stacey Witt
switt@loadspring.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release
The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom